Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3826 Prognostic value of the neutrophil/lymphocyte ratio (NLR) in advanced, non resectable, progressive pancreatic and midgut NET after combine therapy using Lu-177 DOTATOC and CAPTEM

Introduction: Previous data suggest neutrophil/lymphocyte ratios (NLRs) could be used as prognostic factor in various solid tumors.

Conference:

Presenting Author: Kolasińska-Ćwikła A

Authors: Ćwikła J, Kolasińska-Ćwikła A, Zrajkowska A, Pałucki J, Seklecka N,

Keywords: Neuroendocrine Tumor, Receptor, Somatostatin, CAPTEM radioligand therapy (RLT), Progression-Free Survival, Neutrophil lymphocyte ratio,

#3819 Dosimetry evaluation in 177Lu-labeled somatostatin receptor analogue therapy

Introduction: Dosimetry reporting in patients receiving PRRT is fundamental to ensure the safety and efficacy of treatment.

Conference:

Presenting Author:

Authors: Cichoński A, Kempińska-Wróbel M, Kolasińska-Ćwikła A, Zrajkowska A, Szarowicz A,

Keywords: radionuclide therapy, dosimetry, lutetium,

#3495 PFS evaluation in patients with advanced, non-resectable, progressive GEP-NET treated using combine radioligand/PRRT and CAPTEM therapy

Introduction: Prospective, single-arm, open-label, case series study with assessment the efficacy and safety of combined radioligand therapy (RLT/PRRT) and CAPTEM in advanced, non-resectable progressive GEP-NET (NCT04194125).

Conference:

Presenting Author: Ćwikła J

Authors: Ćwikła J, Kolasińska-Ćwikła A, Zrajkowska A, Nowicka G, Pałucki J,

Keywords: neuroendocrine tumor, combine therapy PRRT and CAPTEM, PFS,

#3267 High efficacy of combined PRRT and CAPTEM therapy based on objective response rate (RECIST) in patients with pancreatic and midgut neuroendocrine tumors (NET)

Introduction: PRRT and chemotherapy might be an option.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Kolasińska-Ćwikła A

Authors: Kolasińska-Ćwikła A, Nowicki , Zrajkowska A, Pałucki , Nowicka G,

Keywords: neuroendocrine tumor, pancreatic, midgut, DCR, ORR,

#3264 Low rate of toxicity of combined PRRT and CAPTEM therapy in patients with advanced, non resectable, progressive pancreatic and midgut neuroendocrine tumors (NET)

Introduction: PRRT with 177Lu-DOTATOC combined with chemotherapy (CAPTEM) is an innovative treatment for progressive, advanced, non-resectable GEP-NETs.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Kolasińska-Ćwikła A

Authors: Zrajkowska A, Kolasińska-Ćwikła A, Nowicka G, Pałucki J, Nowicki M,

Keywords: PRRT and CAPTEM, neuroendocrine tumor, adverse events,